Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women

Pineda-Moncusí, Marta; Garcı́a-Pérez, Miguel A.; Rial, Abora; Casamayor, Guillem; Cos, Maria Lourdes; Servitja, Sònia; Tusquets, Ignasi; Díez-Pérez, Adolfo; Cano, Antonio; Garcia-Giralt, Natàlia; Nogués, Xavier

doi:10.1016/j.maturitas.2018.07.015

Cited by 5 publications

(2 citation statements)

References 29 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison with the control group, we found more patients with VD deficiency (56.1% vs. 37.2%) among the BC patients. Decreased levels of VD in BC patients compared to control subjects were observed previously [ 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ], and our results confirm these findings with the LC–MS/MS methodology. Presented findings could be a result of decreased sun exposure.…”

Section: Discussionsupporting

confidence: 92%

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Kimsa-Furdzik,

Bednarek,

Hibner

et al. 2023

Metabolites

View full text Add to dashboard Cite

Background: The predictive role of vitamin D (VD) in breast cancer (BC) patients’ survival is still being investigated. This paper aims to evaluate the changes in VD metabolites during chemotherapy (CTH) and the predictive role of VD status in Caucasian BC patients treated with CTH. Methods: Vitamin D and its metabolites were assessed with reference LC–MS/MS methodology in 98 consecutive BC patients starting CHT, after 3 and 6 months, and compared to the control group. Results: The frequency of VD deficiency in BC patients was greater than in the control group (56.1% vs. 37.2%). After 6 months of CTH, the number of VD-deficient BC patients slightly increased to 60%. The concentrations of VD active forms [25(OH)D2, 25(OH)D3], and catabolites [24,25(OH)2D3 and 3-epi-25(OH)D3] decreased after 3 and 6 months of CTH compared to the baseline values. Strong positive correlations between concentrations of 3-epi-25(OH)D3 and 25(OH)D in both groups were found. Similar correlations were also observed between 24,25(OH)2D3 and 25(OH)D levels. Kaplan–Meier survival analysis showed significantly longer survival in BC patients without deficiency (>20 ng/mL) at baseline (HR = 2.44 (95% CI 1.07–5.59), p = 0.026). Conclusions: (1) Our data provide further evidence that BC patients before CTH are more VD-deficient than the general population and this deficiency increases further during CTH treatment, as observed using the reference LC-MS methodology. (2) Presented results show that VD catabolism is not affected in BC patients. (3) The poorer survival in VD-deficient BP patients supports the importance of VD supplementation in BC patients with 25(OH)D levels below 20 ng/mL.

show abstract

Section: Discussionsupporting

confidence: 92%

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Kimsa-Furdzik,

Bednarek,

Hibner

et al. 2023

Metabolites

View full text Add to dashboard Cite

show abstract

“…Vitamin D is known to play an important role in musculoskeletal tissues in addition to bone 14 , including muscle 15 , cartilage 16 , and synovium 17 . Previous studies carried out in women with ER+ early breast cancer receiving AI treatment, who also frequently present vitamin D deficiency 18 , provide evidence of the possible effects of vitamin D status on musculoskeletal health 9,19 . In our cohort study, the main musculoskeletal effect of vitamin D supplementation was found in AI-related arthralgia, consistent with a previous study by Prieto-Alhambra et al in 2011 11 .…”

Section: Discussionmentioning

confidence: 99%

Efecto de la suplementación con vitamina D en los efectos secundarios musculoesqueléticos relacionados con los inhibidores de la aromatasa para el cáncer de mama: cohorte B-ABLE

Díaz¹,

Servitja-Santana²,

Foronda

et al. 2021

Rev Osteoporos Metab Miner

View full text Add to dashboard Cite

Objetive: To assess the effect of vitamin D supplementation on musculoskeletal complications related to aromatase inhibitor (AI) treatment in patients with breast cancer. Material and methods: Prospective observational study of women undergoing AI treatment, recruited in the B-ABLE cohort. Patients with baseline serum 25 (OH) D (25-hydroxyvitamin D) levels <30 ng/ml received a 16,000 IU dose of oral calcifediol every 2 weeks. Arthralgia and bone loss related to AIs were assessed at 3 months and 1 year of followup, respectively. The association analyzes of vitamin D status at 3 months with musculoskeletal events were carried out using adjusted multivariate linear regression models. In addition, the association of incident pain, defined as patients without initial joint pain, but with a visual analog scale (VAS) >0 at 3 months, was evaluated using logistic regression. Results: Vitamin D supplementation at the start of AI treatment decreased the risk of both incident arthralgia and its worsening. The effective threshold of 25 (OH) D in serum to reduce joint pain was established at 40 ng/ml. However, this threshold was not significantly related to bone changes at one year of follow-up. However, vitamin D levels were inversely correlated with lumbar spine bone loss (LS) (β=0.177% [95% CI: 0.014 to 0.340]). Conclusions: Vitamin D supplementation aimed at achieving serum 25(OH)D levels of at least 40 ng/ml is protective for arthralgia. Vitamin D levels at three months could predict the risk of bone loss in LS at one year of AI treatment. Therefore, high doses of vitamin D are recommended in these patients, who are more prone to musculoskeletal conditions.

show abstract

Clinical significance of serum 25 hydroxyvitamin D in breast cancer: An Indian scenario

Patel¹,

Patel²,

Gokani³

et al. 2020

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women

Abstract: Severely reduced 25(OH)D levels were detected in patients with breast cancer, particularly after recent chemotherapy. These 25(OH)D levels had partially recovered over the long term, but still remained much lower than in the healthy population.

Cited by 5 publications

References 29 publications

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Efecto de la suplementación con vitamina D en los efectos secundarios musculoesqueléticos relacionados con los inhibidores de la aromatasa para el cáncer de mama: cohorte B-ABLE

Clinical significance of serum 25 hydroxyvitamin D in breast cancer: An Indian scenario

Contact Info

Product

Resources

About